Description

Increased demand in biologic-based drug development is a key factor driving demand for parenteral drug manufacturing. What are key trends and expansions by CDMO/CMOs in parenteral drug manufacturing? DCAT Value Chain Insights rounds up the latest developments among CDMO/CMOs. For the text version of this article visit dcatvci.org. 

Key topics: (see Chapter Markers in drop down menu in audio player above) 

• Recent expansion projects 
• Baxter BioPharma Solutions 
• Vetter 
• Recipharm 
• WuXi STA 
• Jubilant HollisterStier 
• PCI Pharma Services 
• Grand River Aseptic Manufacturing 
• Catalent 
• Thermo Fisher Scientific 
• Lonza  
• Carbogen Amcis 
• Alcami 
• Delpharm 
• Fareva 
• WuXi Biologics 
• IDT Biologika 
• Emergent CDMO  
• BSP Pharmaceuticals 
• Aenova 
• Samsung Biologics  
• Ajinomoto Bio-Pharma Services 
• Selkirk Pharma 
• INCOG BioPharma Services 
• ten23 health 
• Berkshire Sterile Manufacturing 

Sponsor: Vetter Pharma International GmbH 

Links: 

Subscribe to our e-newsletter at www.dcatvci.org 

Follow us on Twitter @DCATvci 

Support the show  

Support the show